Patients with stage III (node-positive) colorectal cancer (CRC) benefit from adjuvant chemotherapy. Patients with stage II (invading muscularis propia or deeper and node-negative) CRC typically receive adjuvant chemotherapy if they have high-risk clinical pathologic features, particularly T4 disease.<\/p>\n\n\n\n
In a randomized trial from Australia, 455 patients with stage II CRC were assigned to standard management that included decision-making for adjuvant chemotherapy based on clinical pathologic features versus management guided by circulating tumor DNA (ctDNA), in which blood samples taken at 4 weeks and 7 weeks were used to identify minimal residual disease and the need for adjuvant chemotherapy. <\/p>\n\n\n\n
Only 15% of patients in the ctDNA group received adjuvant chemotherapy versus 28% in the standard-management group. At 2 years, the ctDNA-guided management group had 93.5% recurrence-free survival compared with 92.4% in the standard-management group. Median time to chemotherapy initiation was longer in the ctDNA-guided group than in the standard-management group (83 vs 53 days). This was driven by time to wait for a ctDNA result, which required 2 weeks for turnaround, and ctDNA testing of specimens obtained at 4 and 7 weeks was not performed until the 7-week sample was drawn.<\/p>\n","protected":false},"excerpt":{"rendered":"
Patients with stage III (node-positive) colorectal cancer (CRC) benefit from adjuvant chemotherapy. Patients with stage II (invading muscularis propia or deeper and node-negative) CRC typically receive adjuvant chemotherapy if they have high-risk clinical pathologic features, particularly T4 disease. In a randomized trial from Australia, 455 patients with stage II CRC were assigned to standard management … Read more<\/a><\/p>\n","protected":false},"template":"","categories":[1768,1769],"tags":[3328,2058,1823,1343,3327,3326,3325],"class_list":["post-12327","ec-news","type-ec-news","status-publish","hentry","category-asge-journal-scan","category-asge-kolon","tag-chemotherapy","tag-colon-2","tag-colorectal-cancer","tag-crc","tag-ctdna","tag-stage-ii","tag-stage-iii"],"_links":{"self":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news\/12327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news"}],"about":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/types\/ec-news"}],"wp:attachment":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/media?parent=12327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/categories?post=12327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/tags?post=12327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}